Discovery in the molecular cardiology research labs could improve immuno-oncology drugs, covid, and influenza vaccines
Texas Heart Institute scientists illuminated a molecular pathway that could one day strengthen the immune response to immunotherapies. The first-in-human study tests the safety, tolerability, and pharmacokinetics of an oral small molecule designed to promote a more robust immune response to vaccinations – such as those for COVID-19 and influenza – and immuno-oncology drugs, such as checkpoint inhibitors.
“If successful, this integrin activator could be a game-changer by significantly increasing the number of patients who benefit from these immunotherapies, ” according to Darren Woodside, Ph.D., Vice President for Research at THI, 7 Hills Pharma co-founder and an inventor of the company’s technology.
